Excelsior Biopharma Cash Flow-to-Debt Ratio
Excelsior Biopharma cash flow-to-debt ratio. Excelsior Biopharma (6496) has a Cash Flow-to-Debt Ratio of -0.03x as of June 2026, meaning its operating cash flow of NT$-20.04 Million could theoretically repay 0% of its total liabilities (NT$728.80 Million) in one year. Check Excelsior Biopharma cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Excelsior Biopharma (2017–2025)
Cash flow-to-debt ratio of Excelsior Biopharma from 2017 to 2025. Historical debt coverage capacity for Excelsior Biopharma across 9 annual periods. Check Excelsior Biopharma (6496) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Excelsior Biopharma Cash Flow-to-Debt Ratio by Year (2017–2025)
Excelsior Biopharma cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Excelsior Biopharma. For the full cash flow conversion analysis, see 6496 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.20x | NT$-138.72 Million | NT$679.78 Million | ▼ -20.0% |
| 2024 | -0.17x | NT$-99.80 Million | NT$586.89 Million | ▲ +40.3% |
| 2023 | -0.28x | NT$-134.75 Million | NT$472.87 Million | ▼ -2736.3% |
| 2022 | 0.01x | NT$5.49 Million | NT$507.53 Million | ▼ -88.2% |
| 2021 | 0.09x | NT$55.82 Million | NT$608.90 Million | ▼ -89.1% |
| 2020 | 0.84x | NT$520.81 Million | NT$617.15 Million | ▲ +221.3% |
| 2019 | -0.70x | NT$-169.74 Million | NT$244.06 Million | ▼ -248.4% |
| 2018 | 0.47x | NT$126.92 Million | NT$270.88 Million | ▼ -54.5% |
| 2017 | 1.03x | NT$349.47 Million | NT$339.37 Million | — |